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As an anticancer agent, irinotecan (CPT-11) has been widely applied in clinical, especially
in the treatment of colorectal cancer. However, its clinical use has long been limited
by the side effects and potential tissue toxicity. To discriminate the target toxic tissues
and dissect the specific response of target tissues after CPT-11 administration in rats,
untargeted metabolomic study was conducted. First, differential metabolites between
CPT-11 treated group and control group in each tissue were screened out. Then,
based on fold changes of these differential metabolites, principal component analysis
and hierarchical cluster analysis were performed to visualize the degree and specificity
of the influences of CPT-11 on the metabolic profiles of nine tissues. Using this
step-wise method, ileum, jejunum, and liver were finally recognized as target toxic
tissues. Furthermore, tissue specific responses of liver, ileum, and jejunum to CPT-11
were dissected and specific differential metabolites were screened out. Perturbations in
Krebs cycle, amino acid, purine and bile acid metabolism were observed in target toxic
tissues. In conclusion, our study put forward a new approach to dissect target toxic
tissues and tissue specific responses of CPT-11 using metabolomics.
Keywords: CPT-11, metabolomics, jejunum, ileum, liver, tissue specificity
INTRODUCTION
CPT-11 is an anticancer agent derived from camptothecin and has a wide anticancer spectrum
including colorectal, pulmonary, cervical, and ovarian cancer (Mathijssen et al., 2001; Ikeguchi
et al., 2011). In vivo, CPT-11 can be metabolized to its toxic form SN-38 through CE,
and mainly distributed in liver, kidney, spleen, lung, and heart (Bardin et al., 2005; Hatfield
et al., 2011). The wide distribution of CPT-11 and SN-38 in tissues enhanced the potential
risk of tissue toxicity. Intestine was a well-recognized target toxic tissue of CPT-11. The
administration of CPT-11 could cause goblet-cell hyperplasia, epithelial cell line disarrangement,
Abbreviations: CE, carboxylesterase; GC-MS, gas chromatography-mass spectrometry; HCA, hierarchical cluster analysis;
LC-MS, liquid chromatography-mass spectrometry; NTT, non-target tissue; OPLS-DA, orthogonal partial least squares-
discriminant analysis; PCA, principle component analysis; QC, quality control; SN-38, 7-ethyl-10-hydroxycamptothecin;
SN-38G, SN-38 glucuronide.
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and delayed diarrhea (Lima-Júnior et al., 2012; Spyropoulos,
2015). In addition, studies uncovered that CPT-11 has genetic
influences on spleen and liver, and might cause steatohepatitis
(Wang E. et al., 2011; McWhirter et al., 2013).
The clinical application of CPT-11 had been greatly limited
by those side effects and potential tissue toxicity. However,
there are no proper methods to rapidly and accurately identify
the tissue toxicity. In toxicology studies, drug-induced tissue
toxicity could be recognized by several techniques. Biochemical
indicator analysis is the most routine one either in clinical or
laboratory researches. However, the sensitivity of many indicators
is much low. For example, in the evaluation of kidney function,
blood urea nitrogen, and serum creatinine levels are frequently
applied indexes. But only when glomerular filtration rate is
lower than 50% will blood urea nitrogen and serum creatinine
significantly elevate (Bonventre et al., 2010). On the other
hand, some indicators have the problem of poor specificity.
Glutamate pyruvic transaminase and aspartate transaminase
are regularly used to evaluate liver function. However, other
pathological conditions could also lead to the abnormal increases
in glutamate pyruvic transaminase and aspartate transaminase
(Korones et al., 2001). Histopathological examination is another
common used means for the evaluation of drug-induced tissue
toxicity. However, histological lesions often gradually come to
the surface after a long drug administration period. Therefore,
new strategies to sensitively, specially and rapidly recognize tissue
damages induced by medicines are urgently needed.
Metabolomics is a branch of system biology that detects
and quantifies the holistic metabolite compositions and their
variations in integrated biological tissue systems (Bjerrum et al.,
2010). Drug exposure might cause toxic effect on heart, spleen,
lung, liver, and kidney etc., and the effects could be manifested
as the alternation of tissue metabolic profile (Jiang et al., 2012).
Our previous research has revealed the differential metabolites
in serum between CPT-11 treated group and control group
(Wang et al., 2015). In the present study we proposed a new
metabolomics-based strategy, aiming to recognize the target toxic
tissue and dissect the tissue specific responses of CPT-11 in rats.
MATERIALS AND METHODS
Reagents and Chemicals
CPT-11 injection was obtained from Hengrui pharmaceuticals
(Jiangsu, China). Methylamine hydrochloride, N-methyl-N-
trifluoroacetamide, heptadecanoic acid, glibenclamide, pyridine,
and standard compounds used for metabolite identification were
purchased from Sigma–Aldrich (St. Louis, MO, USA). LC-MS
grade reagents including methanol, acetonitrile and ethyl acetate
were obtained from Honeywell (Burdick and Jackson, USA).
Deionized water was purified using a Milli-Q system (Millipore,
USA).
Animal Experiment and Sample
Collection
All animal experimental protocols were according to the guide
for the care and use of laboratory animals (8th edition) released
by the National Research Council of the National Academies,
and all experimental protocol was approved by the Animal
Ethics Committee of China Pharmaceutical University (License
Number: SYXK 2012-0035).
Twenty-four male Sprague-Dawley rats (weighing 200± 20 g)
were purchased from the Sino-British Sippr/BK Lab Animal
Ltd (Shanghai, China) and housed in a temperature-controlled
environment under 12/12 h dark/light cycle. Rats were
acclimatized for a week with a standard rodent diet, and water
was available ad libitum. Before drug administration, rats were
randomly divided into two groups (control group and CPT-
11-treated group, n = 12). At days 1 and 2, rats in CPT-11-
treated group were administered with CPT-11 intravenously at
the dosage of 150 mg/kg once a day for two consecutive days. Rats
in control group received an equal volume of normal saline. Body
weight and diarrhea score were monitored twice per day. At day
5, orbital venous blood samples were collected and prepared for
blood test. After that, rats were euthanized and samples including
jejunum, ileum, cecum, colon, liver, kidney, spleen, lung, and
heart were removed. A portion of those tissues were fixed in 10%
formalin for hematoxylin and eosin staining, and the remaining
were stored at −80◦C until metabolomics study. The strategy of
dosing and sample collection time point was made according to
our pre-experiments, our previous study, and existing literature
(Trifan et al., 2002; Wang et al., 2015).
Sample Preparation for Metabolomic
Analysis
About 100 mg of each tissue were taken and added with precooled
methanol (1:10, W/V). Then the mixtures were homogenized
with a tissue homogenizer (Bioprep-24 homogenizer, China). The
homogenate was then sonicated in an ice bath for 15 min. After
centrifugation (16000 g, 10 min, 4◦C) for twice, the supernatant
were removed.
For GC-MS analysis, a 40 µL aliquot of the supernatant was
added with 80 µL of methanol containing internal standard
(heptadecanoic acid, 5 µg/mL). Thereafter the solution was
vortex-mixed and then centrifuged at 16000 g for 10 min at 4◦C.
Then 80 µL of the supernatant was transferred to a brown glass
vail and 25µL O-methoxyamine hydrochloride (10 mg/mL in dry
pyridine) was added. Subsequently, the solution was incubated
at 37◦C for 90 min and then evaporated to dryness at 50◦C.
Ultimately, 120 µL of N-methyl-N-trifluoroacetamide/ethyl
acetate (1:1, V/V) was added. After incubation for 2 h at 37◦C,
the mixture was analyzed by GC-MS.
For LC-MS analysis, 40 µL aliquot was added with 80 µL
of acetonitrile containing internal standard (glibenclamide,
5 µg/mL). The solution was vortex-mixed and then experienced
two centrifugation at 16000 g for 10 min at 4◦C. Finally, the
supernatant was analyzed by LC-MS.
Instrumental Analysis
Liquid chromatography-mass spectrometry analysis was
performed on Shimadzu ultrafast LC-ion trap time-of flight
MS system equipped with an electrospray ionization source
(Shimadzu, Kyoto, Japan). Chromatographic separation
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was achieved on a Phenomenex Kinetex C18 column
(100 mm × 2.1 mm, 2.6 µm, Phenomenex, USA). The
gradient elution involved a mobile phase consisting of (A) 0.1%
formic acid in water and (B) acetonitrile. The elution program
was from 95% A to 5% A within 20 min and held for 3 min.
The column oven was maintained at 40◦C and the flow rate was
0.4 mL/min. The injection volume was 5 µL. The electrospray
ionization-MS were acquired in both positive and negative ion
mode with the interface voltage of 4.5 and −3.5 kV, respectively.
The scan range was from mass to charge ratio 100 to 1000. The
flow rate of nebulizing gas was 1.5 L/min and pressure of drying
gas was 100 kPa. The temperature of heat block and curved
desorption line were both 200◦C. LCMS solution software
(Shimadzu, Kyoto, Japan) was used for mass spectra acquisition
and chromatograms processing.
Gas chromatography-mass spectrometry analysis was
performed on Shimadzu GC/MS-QP2010 Ultra (Shimadzu,
Kyoto, Japan) equipped with a 30.0 m × 0.25 mm (I.D) fused-
silica capillary column with 0.25 µm Rtx-5MS stationary phase
(Restek, USA). Helium was used as carrier gas and column
flow was 1 mL/min. The injection volume was 1 µL and the
split ratio was 50:1. The column temperature was initially kept
at 70◦C for 3 min and then increased at 10◦C/min to 320◦C,
where it was held for 2 min. The injector temperature, interface
temperature and ion source temperature were set at 250, 200,
and 250◦C, respectively. Ions were acquired in scan mode
with mass to charge ratio from 45 to 600. Mass spectra and
chromatograms were acquired and processed by GCMS solution
software (Shimadzu, Kyoto, Japan).
Data Quality Assurance
Quality control samples were prepared by pooling equal aliquot
of each tissue homogenate and treated congruously with
real samples. In order to monitor the robustness of sample
preparation and the stability of instrument analysis, QC samples
were intermittently injected through the analytical experiment.
During the instrument analysis, all samples from control and
CPT-11-treated group were randomized in order to avoid inter-
batch differences. Unsupervised pattern recognition method
PCA was constructed based on QC samples and real samples to
evaluate the data quality.
Data Preprocessing and Analysis
Each chromatogram obtained was processed by profiling solution
(Version 1.1, Shimadzu, Japan) for peak deconvolution and
alignment. The primary parameters were set referring to
our previous study (Wang et al., 2015). The resulting data
were exported to an Excel table (Microsoft, USA), handled
according to the “80%” rule: only the variables with values
above zero in at least 80% of one or more groups were kept.
Then, the individual ion fragment intensity was normalized
to the sum intensity of all peaks in one chromatogram.
After normalization, variables with relative standard deviation
lower than 30% in QC samples were kept for further data
analysis.
The preprocessed data sets were imported into SIMCA-
P software (Version 13.0, Umetrics, Sweden). Before the
performance of PCA and OPLS-DA, variables were scaled by
Pareto scaling method (van den Berg et al., 2006). In OPLS-DA,
variables with variable importance projection value exceeding
1.0 were screened out for being responsible for the differences
between CPT-11-treated group and control group in OPLS-DA.
Furthermore, Mann–Whitney U test was performed to determine
the significance of each variable using Multi-experiment Viewer
(MeV1).
Potential Biomarkers Identification and
Visualization
Preliminary identification of metabolites detected by GC-MS was
performed with GCMSsolution by comparing with embedded
National Institute of Standards and Technology library. Peaks
with similarity percent more than 70% were assigned for
compound names referring to existing literatures. Metabolites
detected in LC-MS were firstly identified by comparing accurate
mass to charge ratio, retention time and MS/MS fragmentation
patterns with those standard compounds available in our
lab. Other metabolites without standards were identified by
searching online databases like HMDB2 and METIN3 etc. Heat
map was used to visualize the change trends between groups
in each tissue and drawn by using Multi-experiment Viewer
(MeV4).
Target Toxic Tissue Dissecting by HCA
and PCA
Differential metabolites screened out from each tissue were
combined into a new metabolite collection named Data set X (see
Figure 1). Fold change (FC) of each metabolite were calculated
using the following formulas. FCs of metabolites that were not
screened out in certain tissue were replaced with 0.
if Mn < Cave, then FC = (Mn − Cave)/Mn
if Mn > Cave, then FC = (Mn − Cave)/Cave
where Mn represents the value of one metabolite in one tissue in
Data set X, and Cave represent the average value of this metabolite
in control group of this tissue.
After FC calculation, the new data set was defined as Data
set Y. In order to make the data obtained from different tissues
be comparable, zero points were set using the following stepwise
method. Firstly, the same volume of each tissue homogenate were
mixed up and randomly divided into two sub-groups (S1 and S2)
with six samples in each group. Second, the samples in S1 and
S2 group were processed and analyzed using the same method
as other tissues, and only those metabolites covered by Data set
Y were picked out. Third, FC of each metabolite in S2 group
was calculated by dividing with the corresponding mean value
in S1 group. Those FCs were defined as zero points. Finally, a
1http://www.tm4.org/
2http://www.hmdb.ca/
3http://metlin.scripps.edu/
4http://www.tm4.org/
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FIGURE 1 | Strategy for dissecting target tissue and tissue specific
response. NTT: non-target tissue.
new data set was generated by combining zero points with all
tissues named as Data set Z, which was then imported to SPSS
and SIMCA-P software to perform HCA and PCA, respectively.
In HCA, tissues with larger distances were thought as most
affected by CPT-11. And in PCA, the tissues had farther distances
from zero points were recognized as the target toxic tissues of
CPT-11.
Tissue Specific Response Revealed by
OPLS-DA
In order to reveal the tissue specific response of target tissues,
OPLS-DA was performed to discriminate target tissues from the
rest NTT. Differential metabolites were screened out to represent
the specific responses of each target tissue to CPT-11 exposure
(Figure 1).
RESULTS
Blood Test Results
Red blood cell (RBC) count, white blood cell (WBC) count,
platelet count, neutrophil (NEUT) count and lymphocyte
(LYMH) count results were shown in Figure 2. There were
all significant differences between control and CPT-11 treated
groups.
Pathological Analysis
As can be seen in Figure 3, pathological changes were observed
in intestines, liver and kidney. All intestinal tissues were injured
and manifested as epithelial cells degeneration, intestinal villus
shortening and glandular lumen expansion. Ileum was the most
damaged among the four intestinal segments. In liver, mild partial
inflammatory cells infiltration, cell spotty necrosis, eosinophilic
body appearance and vacuolar degeneration were observed. In
kidney, there was mild hydropic degeneration of renal tubular
epithelial cells. No lesion was observed in the rest tissues.
Data Quality Assurance
Data quality was evaluated using QC samples. For data acquired
from both GC-MS and LC-MS, QCs in PCA score plot
clustered well regarding for all the nine tissues, indicating
good reproducibility of the sample process procedure and the
instrumental system.
Metabolic Profiling of Tissues Were
Disturbed by CPT-11
Principal component analysis and OPLS-DA models of all nine
tissues were constructed between control group and CPT-11-
treated group (Supplementary Figure S1). Intestines of rats
including ileum, cecum, colon, and jejunum in CPT-11-treated
group were completely separated from control group in PCA
score plots, suggesting obvious metabolic changes in intestines
were induced due to CPT-11 administration. Finally, 29, 37, 28,
and 28 differential metabolites were screened out in jejunum,
ileum, cecum, and colon, respectively. In addition to intestines,
liver samples of CPT-11-treated group were also greatly separated
with control group in PCA score plot. Ultimately, 32 significantly
changed metabolites were screened out in liver. Only 11
metabolites were found significantly changed in heart, indicating
less influence was induced by CPT-11. Differential metabolites
with change trend between control group and CPT-11-treated
group of different tissues were listed in Supplementary Table S1.
Heat map was utilized to express content difference visually and
the results were shown in Figure 4.
Multivariate Statistical Analysis
Recognized Ileum, Jejunum, and Liver as
Toxic Target Tissues
Figure 5 shows the result of HCA. Distance of two groups
represented the similarity of metabolic changes in each tissue.
Ileum, jejunum, and liver had farther distances from the other
tissues. Besides, PCA score plot (Figure 6) showed the similar
results with HCA. As can be seen from the 2-dimentional
(Figure 6A) and 3-dimentional score plots (Figure 6B),
ileum, liver, and jejunum were completely distinguished from
other tissues and had farther distances from zero points
than all the other tissues. HCA and PCA results indicated
that CPT-11 could cause specific influences on the metabolic
profiles of ileum, liver, and jejunum. Other tissues were less
affected.
Frontiers in Pharmacology | www.frontiersin.org 4 March 2017 | Volume 8 | Article 122
fphar-08-00122 March 8, 2017 Time: 16:13 # 5
Yao et al. Target Toxic Tissues of Irinotecan
FIGURE 2 | Column plots of blood test results. (A) RBC count; (B) WBC count; (C) Platelet count; (D) NEUT count; (E) LYMH count. Mann–Whitney U test,
∗∗p < 0.01, ∗∗∗p < 0.001, in comparison with control group.
Dissecting Tissue Specific Responses to
CPT-11 Using OPLS-DA
Ileum, jejunum, and liver were recognized as toxic target tissues
according to the results of pathological study and multivariate
statistical analysis. For dissecting specific toxic responses to CPT-
11, OPLS-DA was used to screen differential metabolites that
could distinguish toxic target tissues from NTTs (tissues except
liver, ileum, and jejunum).
First, specific responses of ileum to CPT-11 were analyzed
by comparing ileum with NTTs. The two groups could be well
separated with the model parameter Q2 of 0.977 in OPLS-
DA score plot (Figure 7A). Permutation test showed that the
model was not overfitting (Figure 7B). It is indicated that
the change of metabolites in ileum can be distinguished from
NTTs. After variable screening and metabolite identification,
bile acids including cholic acid, deoxycholic acid, taurocholic
acid, taurodeoxycholic acid, and glycocholic acid, pyrimidine,
lyso-phosphatidylethanolamines, metabolites related to energy
metabolism like glucose, citric acid and succinic acid, amino
acids including isoleucine, methionine, histidine, leucine, lysine,
serine, valine, tyrosine, phenylalanine, proline, and threonine,
and ascorbic acid were screened out. Pathway analysis revealed
that the intestinal related toxic responses involved bile acid,
energy and amino acid metabolism.
Jejunum was also distinguished from NTTs according to
OPLS-DA results (Figure 7C), and permutation test showed
that the model was not overfitting (Figure 7D). Differential
metabolites were bile acids like cholic acid and deoxycholic acid,
lyso-phosphatidylethanolamines, linoleic acid, palmitic acid, and
palmitelaidic acid, amino acids including isoleucine, leucine,
proline, tyrosine, serine, valine, and phenylalanine, and uric acid.
In OPLS-DA score plot (Figure 7E), metabolic profile of
liver could be distinguished from NTTs. Permutation test also
showed that the model was not overfitting (Figure 7F). Amino
acids including threonine, methionine, proline, serine, valine,
isoleucine, leucine, lysine, tyrosine, phenylalanine, glutamic acid,
and histidine, free fatty acids including palmitic acid, linoleic acid
and arachidonic acid, taurodeoxycholic acid, succinic acid, and
cholesterol were finally identified as specific responses of liver.
DISCUSSION
Target Toxic Tissues of CPT-11
In the present study, ileum, jejunum, and liver were recognized
as target toxic tissues of CPT-11 in rats. The findings were
in accordance with previous reports that ileum was the most
damaged among all intestinal segments in CPT-11 treated mice
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FIGURE 3 | Hematoxylin and eosin staining of four sections of intestine and other tissues including kidney, liver, spleen, lung, and heart.
(Nakao et al., 2012). CPT-11 is partly transformed into SN-
38 in liver by CEs, and further transformed into SN-38G by
UDP glucuronosyl transferase1A1 in liver. SN-38G is excreted
to ileum together with bile and transformed into SN-38 by
β-glucuronidase produced by gut flora (Takasuna et al., 1996),
which can be toxic to intestinal epithelial cell (Gupta et al., 1994;
Mathijssen et al., 2001). Jejunum was also reported to be damaged
by CPT-11 in some researches since it has large distribution of
CEs which can be an activator for the transformation of CPT-11
to SN-38 (Guichard et al., 1999; Lam et al., 2010). Liver is the
most vital organ for the metabolism and detoxification of CPT-11
(Humerickhouse et al., 2000). It has reported that a long period of
CPT-11 administration could cause steatohepatitis, mechanisms
of which were mitochondrial impairment and inflammation
induced by impaired β-oxidation (Costa et al., 2014). Therefore,
it is not surprising that metabolic profile of liver was greatly
influenced.
Specific Responses of Target Toxic
Tissues
Specific responses of ileum were identified in the present study.
Bile acid metabolism is related to hepatocyte and intestinal
bacteria (Danielsson and Sjovall, 1975), which can be influenced
by intestinal flora disturbance and liver disease. It was reported
that bile acid metabolism can be disturbed in inflammatory bowel
diseases and had close relationship with inflammatory reaction
(Vavassori et al., 2009; Lenicek et al., 2011). Ascorbic acid is an
antioxidant with the capability of rapidly scavenging a number of
reactive oxygen species (Buffinton and Doe, 1995). Ascorbic acid
was in greater quantities in intestine during catabolic conditions
and corresponding high loads of oxidative stress, which was
found in the inflammatory process of ulcerative colitis (Wang
et al., 2008).
Similarly, some specific responses of jejunum to CPT-11 were
recognized. Bile acids in humans are synthesized from cholesterol
in the liver, and conjugated to either glycine or taurine. Bile
salts are secreted into the small intestine as a component of
bile and transformed into deoxycholic acid by gut flora (Ridlon
et al., 2006). CPT-11 was reported to alter intestinal content
of deoxycholic acid which potentiated the suppression of IL-10
and enhanced the intestinal damage (Lin et al., 2012). Dietary
palmitic acid was reported to be able to modulate intestinal
re-growth after massive small bowel resection in rats. It was
reported that linoleic acid could accelerate mucosa regeneration
after small bowel resection (Park et al., 1989). The decreased
amount of linoleic acid might have influences on the repair course
of damaged jejunum.
Also, specific responses in liver were discriminated.
Taurodeoxycholic acid was found to be increased in liver
in the present study, which was consistent with the change
trend in another research about metabolic profiling of bile
acids in livers of CPT-11 treated rats (Fang et al., 2016).
Taurodeoxycholic acid is formed in the liver by conjugation
of deoxycholic acid with taurine and reported to be increased
in non-alcoholic steatohepatitis livers (Lake et al., 2013).
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FIGURE 4 | Heat map of fold-change of metabolites screened out in ileum, jejunum, cecum, colon, heart, lung, liver, kidney, and spleen.
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FIGURE 5 | Hierarchical cluster analysis of fold-change of metabolites screened out in nine tissues. Background filled in red, blue and green were liver,
jejunum, and ileum samples, respectively.
FIGURE 6 | Principal component analysis score plots based on fold-change data of metabolites screened out in nine tissues. (A) Two-dimensional PCA
score plot; (B) Three-dimensional PCA score plot. Liver, jejunum, and ileum samples were highlighted with red circles.
Methionine is a precursor to phosphatidylcholine, the main
phospholipid coating very low-density lipoprotein particles
which carry triglycerides and cholesterol into blood (Vance
and Vance, 1985). Methionine was also proved to stimulate
the secretion of very low-density lipoprotein from cultured
rat hepatocytes under the condition of choline deficiency (Yao
and Vance, 1988). The decrease of methionine could also have
an effect on the synthesis of S-adenosylmethionine which
is related to hepatic oxidative stress and lipid peroxidation
damage (Rinella et al., 2008). Energy metabolism was enhanced
with up-regulated succinic acid and malic acid, which may be
related with the dysfunction of mitochondrion. Palmitic acid
was proved to be beneficial to alcoholic fatty liver due to the
down-regulation of lipid peroxidation (Nanji et al., 1995). In
our research, palmitic acid was decreased specially in liver
tissue which is noxious to liver health especially in abnormal
conditions. Linoleic acid was decreased in liver tissue in this
study and was also reported to be decreased in livers of rats
with non-alcohol fatty liver disease (Wang X. et al., 2011).
Linoleic acid is an important polyunsaturated fatty acid which
was reported to be able to alleviate the steatosis in livers of mice
with non-alcohol fatty liver disease. n-3 polyunsaturated fatty
acid could activate PPAR-α to up-regulate the expression of
gene which participates in fatty acid oxidation in liver (Videla
et al., 2004). Polyunsaturated fatty acid was also reported to
increase the secretion of ApoB-100 to enhance the transport
of triglyceride (Buang et al., 2004). Ethanolamine is the second
most abundant head group for phospholipids existed on cell
membranes and the component of palmitoylethanolamide used
as messenger molecules (Yeagle, 1989; Verme et al., 2005).
The decrease of ethanolamine could interfere the intercellular
message transmission.
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FIGURE 7 | (A) OPLS-DA score plot of ileum and NTTs; (B) Permutation test of OPLS-DA model constructed between ileum and NTTs; (C) OPLS-DA score plot of
jejunum and NTTs; (D) Permutation test of OPLS-DA model constructed between jejunum and NTTs; (E) OPLS-DA score plot of liver and NTTs; (F) Permutation test
of OPLS-DA model constructed between liver and NTTs.
CONCLUSION
Metabolomics combined with multivariate statistical analysis
method was performed to recognize the toxic target tissues
of CPT-11 in rats. Ultimately, liver, ileum, and jejunum was
distinguished as the most affected tissues. Specific metabolites
changed in these target tissues were screened out by OPLS-
DA. It is found that the perturbations of Krebs cycle, amino
acid metabolism, purine metabolism and bile acid metabolism
were occurred in toxic tissues. This work demonstrates
that metabolomics approach is a potentially powerful tool
for recognizing toxic target tissues and can be utilized to
dissect specific biochemical responses of target tissues. It
is believed that the work flow of dissecting target toxic
tissue based on metabolomics and multivariate statistical
analysis could be extended to other drug tissue toxicity
researches.
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